We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name

By LabMedica International staff writers
Posted on 13 Jul 2021
Print article
Illustration
Illustration
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.

While IL, Inova and Biokit have been part of Werfen since 1992, 2009, and 1973, respectively, they will now be known simply as Werfen. The company has been known as Werfen outside of North America since 2014. The strategic hubs for the Company's key business lines will now be led by Chief Operating Officers, and operate as Werfen Headquarters and Technology Centers. Management and organization of Werfen's Commercial Operations in North America will now be consolidated. Field Service and Customer Service functions will be unified across business lines, while Sales, Applications, Marketing and Technical Support will remain specialized.

With a new logo and brand colors, Werfen adopts a new brand identity - evoking innovation and humanity. The new Werfen logo is modern, strong and singular, signifying unity in the company's quest to deliver innovation after innovation, for every patient whose life could depend upon the quality of a test result. The new logo will be incorporated into the company's products and communication vehicles gradually, over time. The legal names for IL, Inova and Biokit, and any contracts or purchasing agreements, are unaffected by this change.

"This transformation represents a natural evolution for Werfen, strengthening our global leadership position in specialized diagnostics, and positively impacting our ability to drive innovation and support our customers," said Carlos Pascual, CEO at Werfen. "By sharing one global identity, with the same vision and strategic objectives, our teams around the world will maximize collaboration to set new standards for products and services in Hemostasis, Acute Care, Autoimmunity and OEM diagnostics."

Related Links:
Werfen

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.